Study Summary
This trial studies a new drug to treat Duchenne muscular dystrophy. It tests safety, how well it works and how it affects the body in healthy adults and people with Duchenne.
- Duchenne Muscular Dystrophy
- Exon 44
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 6 Secondary · Reporting Duration: Day 1-2 (0-24 hours after first dose) (Part A); Day 1-2 (0-24 hours after first dose) (Part B)
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
AOC 1044-CS1 Part A - Single Dose Levels 1-5
1 of 4
AOC 1044-CS1 Part B - Multiple Ascending Dose Levels 1-3
1 of 4
AOC 1044-CS1 Part A - Single Dose: Placebo
1 of 4
AOC 1044-CS1 Part B - Multiple Ascending Dose: Placebo
1 of 4
Experimental Treatment
Non-Treatment Group
64 Total Participants · 4 Treatment Groups
Primary Treatment: AOC 1044-CS1 Part A - Single Dose Levels 1-5 · Has Placebo Group · Phase 1 & 2
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 7 - 45 · Male Participants · 11 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Can individuals aged 55 and above participate in this trial?
"For this clinical trial, candidates must be aged over 7 and under 45 for consideration." - Anonymous Online Contributor
Could I potentially qualify for participation in this experiment?
"This trial seeks 64 participants who are between 7 and 45 years old, suffering from Duchenne or Becker Muscular Dystrophy." - Anonymous Online Contributor
Is this research experiment currently registering participants?
"The trial is still enrolling participants, as evidenced by the recent update to its posting on clinicaltrials.gov dated January 2nd 2023. Initially posted November 9th 2022, it has been open for recruitment since that time." - Anonymous Online Contributor
What is the criterion for admission to this experiment?
"Affirmative. The clinical trial, which was initially posted on November 9th 2022 and has since been updated as of January 2nd 2023, is actively recruiting participants according to the data hosted on clinicaltrials.gov. Approximately 64 patients must be enrolled from 1 medical centre." - Anonymous Online Contributor